1. Home
  2. MQY vs CDNA Comparison

MQY vs CDNA Comparison

Compare MQY & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield Quality Fund Inc.

MQY

Blackrock MuniYield Quality Fund Inc.

HOLD

Current Price

$11.35

Market Cap

839.0M

Sector

Finance

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.63

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MQY
CDNA
Founded
1994
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
839.0M
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MQY
CDNA
Price
$11.35
$20.63
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$26.67
AVG Volume (30 Days)
184.8K
738.6K
Earning Date
01-01-0001
02-25-2026
Dividend Yield
4.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.22
Revenue
N/A
$357,998,000.00
Revenue This Year
N/A
$14.47
Revenue Next Year
N/A
$11.35
P/E Ratio
N/A
$17.12
Revenue Growth
N/A
14.46
52 Week Low
$9.82
$10.96
52 Week High
$12.52
$25.55

Technical Indicators

Market Signals
Indicator
MQY
CDNA
Relative Strength Index (RSI) 39.55 56.01
Support Level $11.28 $20.09
Resistance Level $11.51 $21.09
Average True Range (ATR) 0.09 1.06
MACD -0.03 0.05
Stochastic Oscillator 0.00 77.67

Price Performance

Historical Comparison
MQY
CDNA

About MQY Blackrock MuniYield Quality Fund Inc.

Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: